REGENXBIO Inc. has initiated a pivotal Phase IIb/III clinical trial for diabetic retinopathy, representing a major milestone in the company's gene therapy development program. The announcement led to a 1.27% increase in the company's share price during after-hours trading, signaling investor optimism about the therapeutic potential.
Gene Therapy Pipeline Progress
The diabetic retinopathy trial initiation comes as REGENXBIO continues to advance multiple gene therapy programs across its pipeline. According to the company's Q2 FY25 updates, the Duchenne muscular dystrophy trial remains on track, demonstrating consistent progress in addressing this severe neuromuscular disorder.
Additionally, REGENXBIO's MPS II gene therapy program is advancing toward a Biologics License Application (BLA) submission, indicating the company's commitment to bringing multiple gene therapies to market for rare diseases.
Analyst Coverage and Market Response
The gene therapy company maintains strong analyst support despite some price target adjustments. Barclays continues to rate REGENXBIO with an Overweight rating and a price target of $37, while RBC Capital maintains an Outperform rating, though the firm reduced its price target to $17 from $21.
Upcoming Financial Disclosure
REGENXBIO is scheduled to discuss its Q2 2025 financial results and operational highlights during a conference call on August 7, 2025. This presentation will likely provide additional details about the diabetic retinopathy trial and other pipeline developments.
The initiation of the pivotal Phase IIb/III trial for diabetic retinopathy represents a significant step forward for REGENXBIO's gene therapy platform, potentially addressing a major unmet medical need in ophthalmology while advancing the company's clinical development strategy.
